Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.
Ulrik Lassen, MD, PhD, head of the Phase I Unit at Rigshospitalet, discusses TRK fusions in pediatric patients with cancer.
Umamaheswar Duvvuri, MD, PhD, Assistant Professor of Otolaryngology (ENT) at the University of Pittsburgh Medical Center, talks about potential genetic signatures for locally advanced, well differentiated thyroid cancers.
Umberto Capitanio, MD, FEBU, department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.
Umberto Malapelle, PhD, assistant professor, University of Naples Federico II, discusses unanswered questions regarding the role of tumor mutational burden in non–small cell lung cancer.
Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses challenges with a trial (NCT00193791) conducted by Tata Memorial Hospital seeking to solidify the impact of concomitant chemoradiation with FIGO stage IIIb squamous cervical cancer.
The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.
I am still juggling tasks as I try to balance my life at home and life at work.
Top researchers will present abstracts on latest clinical research advancing cancer treatment options.
After having devoted the last decade to countless hours in medical school and internal medicine training, you have arrived on the final path of your ultimate career destination.
Vaibhav Sahai, MBBS, assistant professor of medicine at the University of Michigan, discusses sequencing strategies in metastatic pancreatic cancer.
This pilot trial is the first of its type to investigate T cell receptor alpha/beta-depleted and CD19-depleted haploidentical stem cell grafts in relapsed/refractory lymphoma patients.
Valentin Goede, MD, from the University Hospital Cologne, discusses the efficacy findings from the stage 2 CLL11 study that examined obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia with comorbidities.
Vamsidhar Velcheti, MD, discusses the significance of the FDA approval of the ROS1 TKI repotrectinib in patients with ROS1-positive metastatic non–small cell lung cancer.
Vamsidhar Velcheti, MD, discusses the importance of real-world data for patients with non–small cell lung cancer.
Van K. Morris, MD, discusses the evaluation of circulating tumor as a predictive biomarker for the use of adjuvant chemotherapy in patients with low-risk, stage II colon cancer.
Immunotherapy's promise as well as its challenges as a treatment for patients with brain cancer was the focus of a plenary session held November 15 at the Society of Neuro-Oncology's (SNO) 2014 Annual Meeting in Miami Beach.
Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the implications of the NILE trial in non–small cell lung cancer (NSCLC).